Section Arrow
IDYA.NASDAQ
- IDEAYA Biosciences
Quotes are at least 15-min delayed:2025/09/12 15:12 EDT
Regular Hours
Last
 24.76
-0.17 (-0.68%)
Day High 
25.49 
Prev. Close
24.93 
1-M High
27.69 
Volume 
526.81K 
Bid
24.73
Ask
24.77
Day Low
24.665 
Open
24.94 
1-M Low
22.82 
Market Cap 
2.18B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 25.15 
20-SMA 24.88 
50-SMA 23.84 
52-W High 37.8 
52-W Low 13.45 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.84/-2.81
Enterprise Value
2.20B
Balance Sheet
Book Value Per Share
10.95
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
7.00M
Operating Revenue Per Share
0.27
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADAPAdaptimmune Therapeutics plc0.0525+0.002+3.96%-- 
COCPCocrystal Pharma1.6429+0.2029+14.09%-- 
MRNAModerna23.639-1.751-6.90%-- 
RXRXRecursion Pharmaceuticals4.8401-0.0099-0.20%-- 
ETHZETHZilla Corporation2.56+0.15+6.22%-- 
Quotes are at least 15-min delayed:2025/09/12 15:12 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.